ReviewProblemy endokrinologii2025
[Factors and conditions affecting transcortin production and function in blood plasma].
Review in Problemy endokrinologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
It is well-established that the majority of steroid hormones in the bloodstream are in a bound state, complexed with carrier proteins. Transcortin (corticosteroid-binding globulin, SERPINA6) serves as the principal transport protein for steroid hormones and is predominantly synthesized in the liver. Its primary function is to regulate the systemic bioavailability of glucocorticoids and mineralocorticoids. This review article presents an analysis of the existing literature on the impact of various factors and conditions on Transcortin, encompassing its synthesis, secretion, and affinity, as well as its role in physiological and pathophysiological processes within the human body. A reduction in Transcortin levels has been observed in several contexts, including old age, obesity, and metabolic syndrome. Additionally, this decrease is evident in the presence of cirrhosis, sepsis, polytrauma, extensive burns, and during surgical interventions. The concentration of Transcortin in the bloodstream can be influenced by a variety of medications. For instance, estrogen therapy, such as combined oral contraceptives, has been shown to induce a significant increase in Transcortin levels. Conversely, the administration of glucocorticoids has been associated with a decrease in Transcortin levels. Furthermore, this review article includes an analysis of studies that have investigated the influence of Transcortin and alterations in its blood levels in the context of endogenous hypercortisolism. These studies contribute to a deeper understanding of the complex interplay between Transcortin and steroid hormone regulation in various physiological and pathological conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.